Figure 2. Interpretation of Paraneoplastic Antibody Evaluation, CSF, Basic (Test Code 94536) Panel

Patient with suspected paraneoplastic neurological syndrome

Paraneoplastic Antibody Evaluation, CSF, Basic

Reflex Tests

AMPAR1, AMPAR2, GABABR, NMDAR1, CASPR2, LGI1 suggested by tissue IFA

AMPAR1, AMPAR2, GABABR, NMDAR1, CASPR2, LGI1 (CBA)

Titer for positive antibody

AMPAR1, AMPAR2, or GABABR titer ≥1:10

Encephalomyelitis or limbic encephalitis

AMPAR1, AMPAR2, GABABR, NMDAR1, CASPR2, LGI1 (CBA)

NMDAR1 titer ≥1:10

Encephalitis with psychiatric manifestations, seizures, dyskinesias, dystonia, and autonomic instability

CASPR2 or LGI1 titer ≥1:10

Limbic encephalitis, neuromyotonia, or Morvan syndrome

ANNA3 positive by tissue IFA

ANNA3 titer ≥1:10

Encephalomyelitis or sensory neuropathy

NMO antibody suggested by tissue IFA pattern

Aquaporin 4 (NMO), CBA

Positive

Aquaporin 4 (NMO), Titer ≥1:10

Neuromyelitis optica

PCA2 positive by tissue IFA

PCA2 titer ≥1:10

Encephalomyelitis, cerebellar degeneration

AGNA/SOX1, amphiphysin, ANNA1, ANNA2, CRMP5/CV2, GAD65, PCA1, or PCA-Tr (DNER) positive, indeterminate, or suggested by IFA

Western line blot, Quantitative

Positive (signal intensity ≥11)

Refer to Table for interpretation

VGKC, LGI1, CASPR2 antibody suggested by tissue IFA pattern

Neuronal (V-G) K+ Channel Ab, CSF

≥20 pmol/L

Refer to Table for interpretation


Content reviewed 3/2017

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2017 Quest Diagnostics Incorporated. All rights reserved.